Early Access

Accelerate your research with Illumina Protein Prep, powered by SOMAmer technology integrated on Illumina’s NovaSeq X Plus platform.

Unlock the future of Proteomics. Download the full protein list today and explore the precision of SOMAmer for breakthrough discoveries.

Download Protein List

Key Benefits

Why this Proteomics Set-up is for you?

SOMAmer technology enables detection of thousands of proteins with unmatched precision and scalability. Hosted in Eurofins Genomics’ UK facility and compatible with Illumina’s NovaSeq xPlus system, this solution supports a seamless research experience for comprehensive insights into protein function.

High sensitivity and specificity for detecting up to 9,500 unique proteins.
Scalability for high-throughput studies and streamlined workflows, all in under 10 working days from sample to integrated data analysis.
Unmatched precision with mean CV as low as 5.4%, enabling accurate detection of subtle biology with fewer samples.
Deeper insights across 200+ biological pathways, including oncology, immunology, neurology and cardiology.
Early Access Benefits: Join our beta program and receive a special offer as one of the first users during this exclusive launch phase!

How it works:

With streamlined processes from sample preparation to data analysis, Eurofins Genomics and Illumina make proteomics research efficient and effective. SOMAmer’s unique high-affinity detection, combined with Illumina’s sequencing power, offers quick, accurate results with minimal hands-on time.

Applications:

SOMAmer Plasma Proteomics enables research across key biological pathways like oncology, cardiology, immunology, and neurology, revealing new insights into disease mechanisms and potential treatments.

Ready to Advance Your Proteomics Research?

Download our protein list now to explore the full spectrum of detectable proteins.

Download Protein List

Early Access Program

Be among the first to experience SOMAmer Plasma Proteomics with our Early Access program, featuring flexible flow cell options and a special offer for early users. Supported by Eurofins Genomics’ infrastructure, this beta access provides a unique opportunity to advance your research.